Login to Your Account

Clinic Roundup

Monday, January 24, 2011
Chelsea Therapeutics International Ltd., of Charlotte, N.C., reported new 12-month data from Study 303, a safety extension study from its Phase III Northera (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription